Jefferies Group’s Standard BioTools LAB Stock Holding History

Jefferies Group’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-39,895	Closed	-$185K	–	2773
2019 Q3	$185K	Buy	+39,895	New	+$314K	﹤0.01%	2396
2014 Q2	–	Sell	-29,243	Closed	-$1.29M	–	2239
2014 Q1	$1.29M	Buy	+29,243	New	+$1.29M	0.01%	806

Other funds holding LAB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.31B AUM 18.17% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Jefferies Group's LAB Position: Q4 2019 in Review

Jefferies Group sold out of Standard BioTools (LAB) in Q4 2019, closing a stake of 39,895 shares — an estimated $185K sold.

Jefferies Group first reported a position in LAB in Q1 2014 and held it in 2 quarters. The position peaked at $1.29M in Q1 2014. 99 funds tracked by Wall St. Rank hold LAB as of Q4 2019.

Jefferies Group reported no remaining Standard BioTools position as of Q4 2019 after selling out during the quarter.
Jefferies Group sold 39,895 Standard BioTools shares in Q4 2019, an estimated $185K.
Jefferies Group first reported a position in Standard BioTools in Q1 2014 and held it in 2 quarters.
Jefferies Group's Standard BioTools position peaked at $1.29M in Q1 2014.
99 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2019.

Based on Jefferies Group's 13F filing for Q4 2019, filed 13 Feb 2020.